10 Aug 15 Zynerba Pharmaceuticals Announces Closing of Its Initial Public Offering and Exercise in Full of Option to Purchase Additional Shares
Full Answer
When did zynerba pharmaceuticals go public?
(ZYNE) raised $42 million in an initial public offering on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers. What is Zynerba Pharmaceuticals' stock symbol?
What is the upside for zynerba pharmaceuticals (Zyn) stock?
Their forecasts range from $7.25 to $18.00. On average, they anticipate Zynerba Pharmaceuticals' share price to reach $10.56 in the next twelve months. This suggests a possible upside of 229.0% from the stock's current price. View analysts' price targets for Zynerba Pharmaceuticals or view top-rated stocks among Wall Street analysts.
How much is a share of zynerba worth?
One share of ZYNE stock can currently be purchased for approximately $3.21. How much money does Zynerba Pharmaceuticals make? Zynerba Pharmaceuticals has a market capitalization of $132.31 million and generates $90 thousand in revenue each year.
What are analysts'target prices for zynerba Pharmaceuticals'stock?
7 brokers have issued 1-year target prices for Zynerba Pharmaceuticals' stock. Their predictions range from $11.00 to $36.00. On average, they anticipate Zynerba Pharmaceuticals' share price to reach $22.00 in the next year.
Should I buy or sell Zynerba Pharmaceuticals stock right now?
2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last twelve months. There are curr...
What is Zynerba Pharmaceuticals' stock price forecast for 2022?
2 analysts have issued twelve-month price objectives for Zynerba Pharmaceuticals' shares. Their forecasts range from $9.00 to $9.00. On average, th...
How has Zynerba Pharmaceuticals' stock price performed in 2022?
Zynerba Pharmaceuticals' stock was trading at $2.88 on January 1st, 2022. Since then, ZYNE shares have decreased by 63.2% and is now trading at $1....
When is Zynerba Pharmaceuticals' next earnings date?
Zynerba Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast fo...
How were Zynerba Pharmaceuticals' earnings last quarter?
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) issued its earnings results on Monday, May, 16th. The company reported ($0.21) EPS for the quarter, top...
Who are Zynerba Pharmaceuticals' key executives?
Zynerba Pharmaceuticals' management team includes the following people: Mr. Armando Anido MBA , Chairman & CEO (Age 64, Pay $993.36k) Ms. Terri...
Who are some of Zynerba Pharmaceuticals' key competitors?
Some companies that are related to Zynerba Pharmaceuticals include Alaunos Therapeutics (TCRT) , Matinas BioPharma (MTNB) , ProPhase Labs (PRPH)...
What other stocks do shareholders of Zynerba Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include (CGC) , Ca...
When did Zynerba Pharmaceuticals IPO?
(ZYNE) raised $42 million in an IPO on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Pi...
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on research and development of rare and near-rare neuropsychiatric conditions. The firm offers Zygel product, which formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L.
Headlines
Zynerba announces clinical updates for Fragile X and 22q11.2...Zynerba announces clinical updates for Fragile X and 22q11.2...
Investors appear to be worried about potential safety issues with its cannabinoid gel
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
What happened
Shares of Zynerba Pharmaceuticals ( NASDAQ:ZYNE) were crashing 18.3% lower as of 10:48 a.m. EDT on Wednesday after falling as much as 26.5% earlier in the morning.
So what
CEO Armando Anido said that the company is "encouraged by the positive top-line results" of the Believe 1 phase 2 study of Zygel in DEE. How could the results be "positive" and Zynerba's shares fall so hard? It boils down to which part of the results receive the most attention.
Now what
It's quite possible that today's sell-off was overdone. Zynerba could bounce back some over the next few weeks. The company plans to complete its analysis of the data from the Believe 1 study and meet with the Food and Drug Administration sometime in the first half of 2020 to discuss a potential pathway to approval.
What is Stock Sentiment?
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
What's Happening With ZYNE Stock Today?
Zynerba Pharmaceuticals Inc (ZYNE) stock is higher by 0.45% while the S&P 500 is lower by -0.16% as of 2:01 PM on Tuesday, Sep 7. ZYNE is higher by $0.02 from the previous closing price of $4.45 on volume of 1,706,111 shares. Over the past year the S&P 500 has gained 35.91% while ZYNE is higher by 23.82%.
More About Zynerba Pharmaceuticals Inc
Zynerba Pharmaceuticals Inc is a pharmaceutical company that is focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery.
